NRP1 antagonism as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis
Allergy · 2024
DOI: 10.1111/all.16285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von Roza Khalmuratova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Obstructive Upper airway Research (OUaR) Laboratory, Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Neuropilin-1, Rhinitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background
Neuropilin‐1 (NRP1) is expressed on the surface epithelium of respiratory tract and immune cells, demonstrating its possible function in regulating the immune response in airway disease. However, its role in patient with chronic rhinosinusitis (CRS) remains unknown. This study aimed to elucidate the role of NRP1 in CRS with nasal polyps (CRSwNP).
Methods
Sinonasal biopsy specimens were immunohistochemically stained to investigate NRP1 expression. Double immunofluorescence, immunoblotting, and real‐time polymerase chain reaction were performed to evaluate NRP1 in primary human nasal epithelial cells (hNECs). An NRP1 inhibitor was administered to a murine nasal polyp (NP) model.
Results
NRP1 was highly expressed in the epithelium in patients with CRSwNP compared to nasal tissue from controls and CRS without NP patients. NRP1 and vascular endothelial growth factor were upregulated in hNECs under hypoxia. Treatment with NRP1 inhibitor (EG00229) reduced the secretion of interleukin (IL)‐1β, IL‐6, IL‐8, and IL‐33 cytokines, as well as inducible nitric oxide synthase, cyclooxygenase‐2, and prostaglandin E2 in hNECs. We found that NRP1 was highly expressed in the airway epithelium in the murine NP model. The group treated with the NRP1 inhibitor had significantly fewer nasal polypoid lesions and reduced accumulations of immune cells.
Conclusions
These findings reveal that NRP1 is upregulated in CRS and NP epithelium, and the inhibition of NRP1 may lead to a reduction in NP growth and immune cell infiltration. Our results suggest that NRP1 inhibition could be a novel possibility for treating nasal polyposis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obstructive Upper airway Research (OUaR) Laboratory, Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea.
- Ischemic Hypoxia Disease Institute, Seoul National University Medical Research Center, Seoul, Korea.
- Department of Otorhinolaryngology-Head and Neck Surgery, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea.
- Department of Biomedical Informatics, College of Medicine, Konyang University, Daejeon, Korea.
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.
- Sensory Organ Research Institute, Seoul National University Medical Research Center, Seoul, Korea.
ORCID-Profile: Roza Khalmuratova, Jae-Sung Ryu, Ji Hyeon Hwang, Yi Sook Kim, Suha Lim, Ji-Hun Mo, Jong-Yeup Kim, Hyun-Woo Shin
Förderung
- National Research Foundation of Korea
Zitieren
APA
Khalmuratova, R., Ryu, J. S., Hwang, J. H., Kim, Y. S., Lim, S., Mo, J. H., Kim, J. Y., & Shin, H. W. (2024). NRP1 antagonism as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. Allergy. https://doi.org/10.1111/all.16285
Vancouver
Khalmuratova R, Ryu JS, Hwang JH, Kim YS, Lim S, Mo JH, et al. NRP1 antagonism as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. Allergy. 2024. doi:10.1111/all.16285
BibTeX
@article{Khalmuratova2024,
author = {Khalmuratova, Roza and Ryu, Jae-Sung and Hwang, Ji Hyeon and Kim, Yi Sook and Lim, Suha and Mo, Ji-Hun and Kim, Jong-Yeup and Shin, Hyun-Woo},
title = {NRP1 antagonism as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis},
journal = {Allergy},
year = {2024},
doi = {10.1111/all.16285}
}
EUVIMED